Latest News

F2G bags €50.8m financing to advance olorofim

Aspergillus spores could become dangerous for people with a weakened immune system. © CDC


by tg

UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.

The €50.8m financing round was led by Cowen Healthcare Investments and includes strong participation from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences.

The Manchester and Vienna-based company announced it will use the proceeds to finance the ongoing Phase IIb proof-of concept study of its antifungal compound olorofim (F901318) and preparatory work for its commercialisation. F901318, a dihydrorotate dehydrogenase (DHODH) blocker, is in a Phase 2b open-label study focussing on rare and resistant life-threatening opportunistic fungal infections, such as invasive aspergillosis, scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and valley fever. Olorofim, F2G’s lead compound from the novel drug class of orotomides that block fungal de novo pyrimidine synthesis, could represent a market opportunity in excess of US$6bn. 

Affimed prices public offering to finance NK cell trials

German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a  $4.00 per common share. A 30-day...

Abliva decides on a SEK200m financing to fund Phase 2/3 study

Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

XNK Therapeutics AB raises €12.75m

XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its  autologous NK cell-based...

International Vaccine Institute – IVI – will locate its European office in Stockholm

The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

Commission to establish EU health data space

The EU Commission is set to present a draft law on a "European health data area" this Tuesday, which could be a big thing for digital...

Roche obtains special authorisation for bispecific antibody

Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...

French ImCheck get´s a USD103m check by Pfizer and a pack of VCs

With around EUR100m in previous financing rounds ImCheck’s financial position looks 'solidified' to take on the leadership in the gamma-delta T cell...